Method for treating autism

• US 20050222272A1
• Filed: 12/21/2004
• Published: 10/06/2005
• Est. Priority Date: 04/05/2004
• Status: Active Grant

• Current Assignee: Forest Laboratories Holdings Limited (Abbvie Incorporated)
• Original Assignee: Forest Laboratories Holdings Limited (Abbvie Incorporated)
• Inventors: Chez, Michael Gene
• Granted Patent: US 7,456,224 B2
• Time in Patent Office: Days
• US Class Current: 514/662
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system

Abstract

A method for treating autism comprising the step of administering an effective amount of a medicament characterized as a NMDA-receptor antagonist or a pharmaceutically acceptable salt thereof.

Claims

1. A method for treating autism, comprising the step of:

administering an effective amount of a medicament characterized as a NMDA-receptor antagonist or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1, wherein the step of administering an effective amount of medicament includes the step of administering the medicament in a concentration ranging from approximately 1 mg to approximately 100 mg per day.

3. The method according to claim 1, wherein the step of administering an effective amount of medicament includes the step of administering the medicament in a concentration ranging from approximately 5 mg to approximately 20 mg per day.

4. The method according to claim 1, wherein the step of administering an effective amount of a medicament includes the step of administering an effective amount of a medicament represented by the following chemical structure:

5. The method according to claim 4, wherein the step of administering an effective amount of medicament includes the step of administering the medicament in a concentration ranging from approximately 1 mg to approximately 100 mg per day.

6. The method according to claim 4, wherein the step of administering an effective amount of medicament includes the step of administering the medicament in a concentration ranging from approximately 5 mg to approximately 20 mg per day.

7. The method according to claim 1, wherein the step of administering an effective amount of a medicament includes the step of administering an effective amount of a medicament represented by the following chemical structure:

8. The method according to claim 7, wherein the step of administering an effective amount of medicament includes the step of administering the medicament in a concentration ranging from approximately 1 mg to approximately 100 mg per day.

9. The method according to claim 7, wherein the step of administering an effective amount of medicament includes the step of administering the medicament in a concentration ranging from approximately 5 mg to approximately 20 mg per day.

10. The method according to claim 1, wherein the step of administering an effective amount of a medicament includes the step of administering an effective amount of a medicament represented by the following chemical structure:

11. The method according to claim 10, wherein the step of administering an effective amount of medicament includes the step of administering the medicament in a concentration ranging from approximately 1 mg to approximately 100 mg per day.

12. The method according to claim 10, wherein the step of administering an effective amount of medicament includes the step of administering the medicament in a concentration ranging from approximately 5 mg to approximately 20 mg per day.

13. The method according to claim 1, wherein the step of administering an effective amount of a medicament includes the step of administering an effective amount of a medicament represented by the following chemical structure:

14. The method according to claim 13, wherein the step of administering an effective amount of medicament includes the step of administering the medicament in a concentration ranging from approximately 1 mg to approximately 100 mg per day.

15. The method according to claim 13, wherein the step of administering an effective amount of medicament includes the step of administering the medicament in a concentration ranging from approximately 5 mg to approximately 20 mg per day.

16. The method according to claim 1, wherein the step of administering an effective amount of a medicament includes the step of administering an effective amount of 1-amino-3,5-dimethyladamantane hydrochloride and pharmaceutically acceptable derivatives thereof.

17. The method according to claim 16, wherein the step of administering an effective amount of medicament includes the step of administering the medicament in a concentration ranging from approximately 1 mg to approximately 100 mg per day.

18. The method according to claim 16, wherein the step of administering an effective amount of medicament includes the step of administering the medicament in a concentration ranging from approximately 5 mg to approximately 20 mg per day.

19. A method for treating autism, comprising the step of:

administering an effective amount of a medicament represented by the following chemical structure;

wherein X₁ comprises CH₂ or R₁₅;

wherein R_1-15 are the same or different and comprise H, an amino group, a primary amine, a secondary amine, a tertiary amine, a quaternary ammonium group, a hydroxy group, a straight or branched alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkenyl, alkynyl group containing approximately 1 to approximately 50 carbon atom(s), a silyl or siloxyl group containing approximately 1 to approximately 50 silicon atom(s), and combinations thereof; and

wherein the step of administering the medicament includes the step of administering the medicament in a concentration ranging from approximately 5 mg to approximately 20 mg per day.

20. A method for treating autism, comprising the step of:

administering an effective amount of a medicament characterized as a NMDA-receptor antagonist or a pharmaceutically acceptable salt thereof,

wherein the step of administering an effective amount of a medicament includes the step of administering an effective amount of 1-amino-3,5-dimethyladamantane hydrochloride and pharmaceutically acceptable derivatives thereof, and

wherein the step of administering an effective amount of medicament includes the step of administering the medicament in a concentration ranging from approximately 5 mg to approximately 20 mg per day.